TL;DR: How GlycanAge is Innovating Preventive Healthcare Diagnostics
GlycanAge is transforming healthcare by integrating glycan biomarkers into hospital diagnostics, moving beyond the niche "longevity wellness" market. Their glycan-based tests dynamically measure inflammation and immune health, enabling early disease detection and personalized prevention.
• Why glycans matter: They provide actionable, modifiable insights into chronic diseases, unlike static genetic data.
• Funding success: Raised $8.7M to expand globally, secure regulatory approvals, and scale in hospitals.
• Lessons for founders: Prioritize regulatory compliance, scalability, and actionable solutions to bridge niche innovations to mainstream adoption.
Startups can emulate GlycanAge's science-driven strategy to blend innovation with practical impact. Learn more about their journey at The Recursive.
Check out other fresh news that you might like:
Startup News: How to Avoid Mistakes and Learn from WPBeginner’s Best WordPress Tips for 2026
Startup News 2026: Tips and Lessons from Six Innovators Redefining Industries Globally
The integration of scientific advancements into everyday healthcare isn’t new, but GlycanAge is aiming to do something extraordinary. It’s not merely about offering another biomarker for tracking wellness; it’s about shifting the narrative entirely, turning preventive tools into routine hospital diagnostics. For founders looking up to transformative models for inspiration, here’s a masterclass in how science meets market expansion. I encountered GlycanAge during my exploration of startups that merge deep science with practical, actionable innovations, and trust me, their trajectory is one to watch.
Why is this significant? Because moving from the niche “longevity wellness” markets into regulated hospital diagnostics is a Herculean task. For science startups, regulatory labyrinths, customer education, and securing funding often turn into overwhelming barriers. Yet GlycanAge is pushing forward, bringing glycan-based biomarkers to hospitals worldwide to combat major health challenges like heart disease and hormonal imbalances. Their founders, Gordan and Nikolina Lauc, are setting new standards for leveraging glycoscience, which could significantly alter how diagnostics work in preventative medicine globally.
Why Are Glycans So Critical in Modern Diagnostics?
Most diagnostic tools today heavily rely on genetic information. While genetics can predict predispositions and offer insights into some acute conditions, chronic diseases and aging-related health issues remain largely unexplored through genetic testing. Glycans, on the other hand, provide dynamic signals reflective of inflammation, metabolic changes, and overall immune health over time, making them actionable biomarkers. GlycanAge uses IgG glycosylation patterns, which shift based on your lifestyle, genetics, and environment. This makes glycan profiling an exciting leap toward dynamic, modifiable diagnostics.
- Dynamic nature: Glycans adapt to your body’s inflammation levels and immune response.
- Early detection: Changes in glycan profiles can signal disease risk years before symptoms appear.
- Global application: GlycanAge tests are now being deployed in hospitals such as St. Catherine Specialty Hospital in Croatia and via CLIA-certified labs globally.
Here lies the future: diagnostics that don’t just provide static data but evolve with your health. Glycans are poised to revolutionize cardiovascular risk screening, secondary prevention therapies, and women’s health, all areas that currently rely on less precise diagnostic tools.
How Did GlycanAge Secure $8.7M to Expand Their Model?
In December 2025, GlycanAge closed an impressive $8.7M funding round aimed at accelerating their transition from longevity clinics into regulated hospital diagnostics. This milestone was key to their scaling plans, including expanding into global territories. Investors such as Guinness Ventures and LAUNCHub Ventures played a crucial role in backing the company’s scientific ambition.
- Focus of Funding: They’re targeting regulatory approval frameworks (IVDR in Europe) and integrating glycan testing across regions like Asia, Europe, and the Middle East.
- Hospital Deployment: Machines are already operational in hospitals in China and Croatia, with further plans to expand.
- Revenue Diversification: Over 60% of GlycanAge’s current revenue comes from the U.S., despite lacking a permanent staff presence.
As someone deeply involved in the startup world, I know securing funding requires more than just big ideas. The GlycanAge founders demonstrated clear vision and practicality in their pitch, projecting a 5, 10X ROI within the first quarter of integration, all while pushing the boundaries of science-backed insights into hospital settings. Check out their funding success story at The Recursive.
What Can Founders Learn From GlycanAge’s Expansion Strategy?
For entrepreneurs trying to bridge the gap between niche markets and mainstream adoption, GlycanAge is the blueprint. Their strategic pivot from being a “wellness” company primarily serving longevity clinics to becoming hospital-integrated diagnostics highlights several key lessons:
- Understand regulatory hurdles: Moving into hospital diagnostics requires compliance with rigorous testing, certification, and IVDR approvals.
- Prioritize scalability: By successfully deploying in high-profile hospitals like St. Catherine Specialty Hospital, they showcased scalable systems.
- Focus on actionability: GlycanAge made sure their diagnostics provide modifiable feedback, a game-changer for customer engagement and retention.
For founders in deeptech and biotech, two questions are critical: How will your innovation integrate into existing workflows? And can you demonstrate measurable outcomes that resonate with decision-makers? GlycanAge managed to do both seamlessly.
What Challenges Did They Overcome?
Scaling into hospital diagnostics isn’t just about science; it’s about proving reliability. The GlycanAge team faced significant obstacles, from tackling regulatory procedures in Europe and setting up clinical validation pipelines to educating stakeholders about glycobiology’s potential in preventive medicine. Yet through targeted research collaborations (e.g., the Human Glycome Project), they attained breakthroughs that fueled credibility. Their next hurdle? Scaling globally without losing their focus on quality.
Conclusion: Is GlycanAge Redefining Hospital Diagnostics?
For science-driven startups, GlycanAge offers a compelling case study on how you can integrate cutting-edge technology into traditional structures like hospitals and healthcare systems, transforming patient outcomes in the process. What stands out most? Their resiliency and ability to transition beyond just wellness markets into regulated hospital spaces, a leap that many startups never complete. As this company grows, its impact will stretch far beyond biomarkers, it might just redefine how preventive diagnostics shape healthcare globally.
Are you building your own startup? Think about how GlycanAge leveraged an academic foundation, robust funding strategy, and niche-to-mainstream pivot. It’s a model worth copying if you’re aiming to blend deep science with massive impact. Dive deeper into their journey using resources from The Recursive.
FAQ on GlycanAge and Its Impact on Modern Hospital Diagnostics
What makes GlycanAge unique in the field of diagnostics?
GlycanAge stands out as a leader in glycan-based biomarkers that track dynamic health changes. Unlike most diagnostic tools that focus exclusively on static genetic information, GlycanAge uses IgG glycosylation patterns to monitor inflammation, immune response, and lifestyle-related variations. This intricate approach makes their diagnostics modifiable and actionable, offering early detection capabilities for chronic diseases like cardiovascular ailments and better insights into hormonal health. GlycanAge has successfully transitioned from the niche “wellness” industry into regulated hospital diagnostics, offering a new level of precision in preventive healthcare. Explore Glycan biomarkers with GlycanAge
Why are glycans critical in modern diagnostics?
Glycans, sugar molecules attached to proteins, provide dynamic insights into immune health and metabolic changes. Glycan profiling is instrumental in early detection as it can signal disease risks years before symptoms emerge. For instance, GlycanAge enables early identification of cardiovascular risks and women's health conditions by assessing inflammation and hormonal shifts reflected in glycan patterns. This stands as a transformative step toward personalized medicine, overcoming the limitations of conventional genetic diagnostics that cannot account for modifiable lifestyle factors. Understand the value of glycan testing
How is GlycanAge integrating into hospitals?
GlycanAge is making waves by integrating glycan-based diagnostic tools into mainstream hospital workflows. The recent deployment at St. Catherine Specialty Hospital in Croatia serves as a groundbreaking model, with glycan biomarkers used for cardiometabolic risk screening and preventive diagnostics. Machines have also been introduced in other global locations like China, allowing clinicians to address chronic diseases effectively. The integration ensures that GlycanAge’s tools aren't just theoretical advancements but practical solutions tailored for hospital environments. Learn about GlycanAge at St. Catherine
How did GlycanAge secure $8.7M in funding?
In December 2025, GlycanAge successfully raised $8.7M in a targeted funding round led by notable investors such as Guinness Ventures and LAUNCHub Ventures. The funds were allocated toward regulatory approvals (e.g., IVDR certification in Europe), global expansion to regions in Asia, the Middle East, and more, as well as further integration into hospital systems. GlycanAge’s co-founders pitched a strong business case, emphasizing their evidence-based solutions and projecting significant ROI within just three months of hospital adoption. Read about GlycanAge's funding success
What challenges has GlycanAge faced in its growth?
Transitioning from wellness biomarker applications to hospital diagnostics wasn’t straightforward. GlycanAge encountered hurdles such as navigating complex European regulatory frameworks like IVDR, establishing clinical validation pipelines, and increasing awareness about glycobiology in preventive medicine. Their collaboration with entities like the Human Glycome Project provided crucial breakthroughs in scaling their glycan technology while maintaining high scientific standards.
How can startups learn from GlycanAge’s strategy?
Startups seeking to scale should take notes from GlycanAge’s approach to bridging niche wellness markets and mainstream diagnostics. Key lessons include understanding regulatory frameworks like IVDR, prioritizing scalability through high-profile hospital deployments, and ensuring their diagnostics offer actionable insights. GlycanAge also showcased the importance of strategically timing funding rounds and scaling in regions with high adoption potential. Learn from GlycanAge’s expansion success
What are GlycanAge's current and future goals?
GlycanAge is focused on scaling its glycan-testing systems globally, with hospital machine deployments already operational in Croatia and China. Future goals include expanding to more public hospitals across Europe, the Middle East, and Asia. They aim to become the global standard in preventive diagnostics, making glycan biomarkers accessible to people aged 30 and above for routine health insights.
What role do glycans play in women’s health diagnostics?
Glycan biomarkers are particularly impactful for hormonal health. GlycanAge has been pivotal in enabling earlier detection of hormone-related conditions, such as perimenopause or imbalances, which are often missed by traditional diagnostics. By providing dynamic, modifiable feedback, their tests allow for precisely tailored preventive interventions.
How does GlycanAge contribute to longevity medicine?
GlycanAge was originally a flagship in longevity medicine, offering tools to assess "biological age" using glycan-based inflammaging clocks. These solutions empowered clinicians to craft personalized lifestyle interventions aimed at slowing biological aging. While the company has transitioned to a focus on hospital diagnostics, its foundational work remains a significant contribution to the longevity industry.
Which regions show the most interest in GlycanAge’s offerings?
The United States currently represents over 60% of GlycanAge’s revenue, despite having no permanent staff presence in the region. Expansion strategies are underway, including setups in Europe, Asia, and the Middle East, highlighting growing interest in dynamic, preventive diagnostics across global markets. Check GlycanAge's global developments
About the Author
Violetta Bonenkamp, also known as MeanCEO, is an experienced startup founder with an impressive educational background including an MBA and four other higher education degrees. She has over 20 years of work experience across multiple countries, including 5 years as a solopreneur and serial entrepreneur. Throughout her startup experience she has applied for multiple startup grants at the EU level, in the Netherlands and Malta, and her startups received quite a few of those. She’s been living, studying and working in many countries around the globe and her extensive multicultural experience has influenced her immensely.
Violetta is a true multiple specialist who has built expertise in Linguistics, Education, Business Management, Blockchain, Entrepreneurship, Intellectual Property, Game Design, AI, SEO, Digital Marketing, cyber security and zero code automations. Her extensive educational journey includes a Master of Arts in Linguistics and Education, an Advanced Master in Linguistics from Belgium (2006-2007), an MBA from Blekinge Institute of Technology in Sweden (2006-2008), and an Erasmus Mundus joint program European Master of Higher Education from universities in Norway, Finland, and Portugal (2009).
She is the founder of Fe/male Switch, a startup game that encourages women to enter STEM fields, and also leads CADChain, and multiple other projects like the Directory of 1,000 Startup Cities with a proprietary MeanCEO Index that ranks cities for female entrepreneurs. Violetta created the “gamepreneurship” methodology, which forms the scientific basis of her startup game. She also builds a lot of SEO tools for startups. Her achievements include being named one of the top 100 women in Europe by EU Startups in 2022 and being nominated for Impact Person of the year at the Dutch Blockchain Week. She is an author with Sifted and a speaker at different Universities. Recently she published a book on Startup Idea Validation the right way: from zero to first customers and beyond, launched a Directory of 1,500+ websites for startups to list themselves in order to gain traction and build backlinks and is building MELA AI to help local restaurants in Malta get more visibility online.
For the past several years Violetta has been living between the Netherlands and Malta, while also regularly traveling to different destinations around the globe, usually due to her entrepreneurial activities. This has led her to start writing about different locations and amenities from the point of view of an entrepreneur. Here’s her recent article about the best hotels in Italy to work from.
